Alvotech Q4 FY2024 earnings call

2024 was a pivotal year for Alvotech. The company had invested around $2 billion over 12 years, leveraging its position as a pure play biosimilar company with end-to-end in-house manufacturing capabilities and global commercial reach to over 90 countries. In 2024, the team delivered 2 million units of finished products, scaled manufacturing quarter by quarter, and had multiple successful launches, including AVT02 in the U.S. and AVT04 in Europe. R&D efforts yielded two major U.S. approvals and accepted filings for three additional projects in global markets. The company passed inspections from global health authorities, secured a private label contract for AVT02, and raised over $300 million in capital, simplifying its capital structure by removing 2025 maturities.

In 2024, Alvotech achieved substantial financial growth. Product revenues exceeded $273 million, representing a 460% increase from the previous year. Total revenues grew over 400% to $492 million. Adjusted EBITDA stood at approximately $108 million, a significant improvement from the $300 million loss in 2023. Product revenues increased quarter by quarter, with margins gradually climbing; gross margins were negative in Q1 but reached 45% in the most recent quarter. The fourth quarter alone saw product revenues of $146 million, marking the third consecutive quarter-over-quarter rise in product revenue. For the full year, adjusted product margins were 33% and adjusted gross margin was 63%, bolstered by licensing and other revenues totaling $219 million.

For 2025, Alvotech projects total revenues in the range of $570 million to $670 million, representing a strong 25% year-on-year growth from the midpoint. Adjusted EBITDA is expected to be between $180 million and $260 million. The company aims to reach $1.5 billion in revenues and a 40%-45% EBITDA margin by 2028. In the 2025-2026 period, sustained growth is anticipated from new biosimilar launches worldwide. The acquisition of Xbrane’s R&D operation in Sweden accelerates development, with three early-stage programs moving to preclinical development in 2024 and plans for four to six new development programs annually going forward.

Risks include intense market competition in the biosimilar space, potential regulatory challenges in obtaining approvals for new products, and intellectual property issues that could impede market entry for certain biosimilars. Additionally, fluctuations in pricing and market dynamics in key regions could impact financial performance.

Q: Thoughts on Stelara pricing and private label deals, and the cadence of milestone revenues?

A: Anil Okay stated that Stelara pricing in the U.S. is early post-launch but optimistic, while in Europe, there is established pricing with assumed price pressure. Private label deals have active discussions ongoing. Joel Morales mentioned that 2025 milestone revenues are driven by progress in R&D, with a higher weighting in the second half of the year. He anticipates cumulatively around $250 million in milestone revenues annually from 2025 to 2028 based on the current pipeline programs.